Addressing the gathering Nadda said that Indian Pharmacopoeia 2026 incorporated 121 new monographs, increasing the total number of monographs to 3,340.
He further noted that coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes.
Referring to pharmacovigilance, Union Health minister stated that, ‘In recent years, the Indian Pharmacopoeia standards have also gained international acceptance as it has become a focused agenda under the health diplomacy of the Government of India.
He also noted that, Indian Pharmacopoeia is now recognised in 19 countries of the global south.
